Sir,

We sincerely appreciate the interest of the author in our review article "Antifungal resistance in dermatology."\[[@ref1]\]

Medical jargon is often described as the second language of healthcare professionals.\[[@ref2]\] The authors agree that varied terminologies can add to the existing confusion. They thereby prefer to adhere to the existing nomenclature pending consensusClinical resistance is defined as the failure to eradicate a fungal infection despite the administration of an antifungal agent with *in vitro* activity against the organism. Clinical resistance depends on various host and drug-related factors.\[[@ref1]\] A knowledge of distinction between clinical and microbiological resistance is required for various causative factors and their therapeutic outcome.Ciclopirox olamine is approved as a topical formulation for superficial mycoses. Studies have shown that itraconazole and terbinafine have a lower minimum inhibitory concentration (MIC) than ciclopirox against *Trichophyton rubrum* and *Trichophyton mentagrophytes*.\[[@ref3]\] Susceptibility tests on *Candida albicans* revealed a lower MIC for itraconazole and ketoconazole when compared to ciclopirox\[[@ref4]\]Antimicrobial drug resistance is an almost inevitable process that is universal in the microbial world.\[[@ref1]\] Ciclopirox also induces change in expression of genes encoding multidrug resistance efflux pumps CDR1 and CDR2.\[[@ref5]\] Considering the above facts and the present nature of dermatophytosis, excessive reliance on any single topical medication for therapeutic goals may be unwarranted.The author highlighted the fungicide usage in agriculture and azole-resistant filamentous fungi in Indian settings.The main focus of our article remained the mechanism of antifungal resistance in dermatology and broad therapeutic outlines. A comprehensive review of antifungal resistance was beyond the scope of the article.
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